Drugs that contain Pomalidomide

1. List of Pomalyst drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8828427 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673939 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(3 months from now)

US8735428 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(3 months from now)

US8735428

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(9 months from now)

US8673939

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(9 months from now)

US8198262 CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Jun, 2025

(2 years from now)

US8198262

(Pediatric)

CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Dec, 2025

(2 years from now)

US9993467 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(7 years from now)

US10555939 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(7 years from now)

US10555939

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(7 years from now)

US9993467

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(7 years from now)

US8828427

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Nov 20, 2023
Orphan Drug Exclusivity (ODE) May 14, 2027
Pediatric Exclusivity (PED) May 20, 2024

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of POMALYST before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic